title: Allografting for indolent lymphoid neoplasms.
abstract: BACKGROUND
  Allogeneic bone marrow transplantation (BMT) has been used in patients with low-grade lymphoma (LGL) and chronic lymphocytic leukemia (CLL) with the goal of achieving long-term disease-free survival.
  
  
  METHODS
  Twenty-nine patients with these diagnoses (LGL = 19, CLL = 10) received allogeneic BMT between September 1995 and January 1999. Median age was 42 (range 20-52) years. Twenty-three of twenty-nine patients (79%) were Ann Arbor or Rai stage IV at the time of transplant; twenty-four (83%) had never achieved complete remission (CR). Donor source was HLA-matched sibling (20), unrelated (8) and syngeneic (1).
  
  
  RESULTS
  Seventeen patients are currently alive, a median of 29 months (range 1-85) post-BMT with a median KPS of 90%. Twenty-three of twenty-seven evaluable patients (85%) achieved CR post-BMT. Six patients had refractory/recurrent disease. Death occurred related to transplant complications in eight patients and underlying disease in four. Overall and event-free survival for the whole group is 51% and 44%, respectively.
  
  
  CONCLUSIONS
  Allogeneic BMT for young patients with advanced stage LGL or CLL is a feasible strategy that can result in achievement of long-term disease-free survival.
authors.affiliation: Division of Hematology, Vancouver Hospital & Health Sciences Centre, Canada.
authors.forename: C L
authors.initials: CL
authors.lastname: Toze
authors.forename: J D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: J M
authors.initials: JM
authors.lastname: Connors
authors.forename: N J
authors.initials: NJ
authors.lastname: Voss
authors.forename: R D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
authors.forename: H G
authors.initials: HG
authors.lastname: Klingemann
authors.forename: S H
authors.initials: SH
authors.lastname: Nantel
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevill
authors.forename: G L
authors.initials: GL
authors.lastname: Phillips
authors.forename: D E
authors.initials: DE
authors.lastname: Reece
authors.forename: H J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: E A
authors.initials: EA
authors.lastname: Conneally
authors.forename: M J
authors.initials: MJ
authors.lastname: Barnett
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000401:mortality* / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome